Antiatherosclerotic and Renoprotective Effects of Ebselen in the Diabetic Apolipoprotein E/GPx1-Double Knockout Mouse by Chew, Phyllis et al.
Antiatherosclerotic and Renoprotective Effects of
Ebselen in the Diabetic Apolipoprotein E/GPx1-Double
Knockout Mouse
Phyllis Chew,
1 Derek Y.C. Yuen,
1 Nada Stefanovic,
1 Josefa Pete,
2 Melinda T. Coughlan,
2
Karin A. Jandeleit-Dahm,
2 Merlin C. Thomas,
2 Franklin Rosenfeldt,
3 Mark E. Cooper,
2
and Judy B. de Haan
1
OBJECTIVE—To investigate the effect of the GPx1-mimetic
ebselen on diabetes-associated atherosclerosis and renal injury
in a model of increased oxidative stress.
RESEARCH DESIGN AND METHODS—The study was per-
formed using diabetic apolipoprotein E/GPx1 (ApoE
/GPx1
/)-
double knockout (dKO) mice, a model combining hyperlipidemia
and hyperglycemia with increased oxidative stress. Mice were
randomized into two groups, one injected with streptozotocin,
the other with vehicle, at 8 weeks of age. Groups were further
randomized to receive either ebselen or no treatment for 20
weeks.
RESULTS—Ebselen reduced diabetes-associated atherosclerosis
in most aortic regions, with the exception of the aortic sinus, and
protected dKO mice from renal structural and functional injury. The
protective effects of ebselen were associated with a reduction in
oxidative stress (hydroperoxides in plasma, 8-isoprostane in urine,
nitrotyrosine in the kidney, and 4-hydroxynonenal in the aorta) as
well as a reduction in VEGF, CTGF, VCAM-1, MCP-1, and Nox2 after
10 weeks of diabetes in the dKO aorta. Ebselen also signiﬁcantly
reduced the expression of proteins implicated in ﬁbrosis and
inﬂammation in the kidney as well as reducing related key intracel-
lular signaling pathways.
CONCLUSIONS—Ebselen has an antiatherosclerotic and reno-
protective effect in a model of accelerated diabetic complications in
the setting of enhanced oxidative stress. Our data suggest that
ebselen effectively repletes the lack of GPx1, and indicate that
ebselen may be an effective therapeutic for the treatment of
diabetes-related atherosclerosis and nephropathy. Furthermore,
this study highlights the feasibility of addressing two diabetic
complications with one treatment regimen through the unifying
approach of targeted antioxidant therapy. Diabetes 59:3198–
3207, 2010
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hronic kidney disease is associated with en-
hanced morbidity and mortality, particularly
caused by accelerated cardiovascular disease
(1). Diabetes is emerging as an independent risk
factor for both chronic kidney disease and atherosclerosis
(2). Diabetic renal and cardiovascular complications are
known to share common underlying pathogenic mecha-
nisms, with oxidative stress and systemic inﬂammation
contributing to both (3,4). Limiting oxidative stress
through the removal of reactive oxygen species (ROS) is
one strategy postulated to limit ROS-mediated chronic
kidney disease and atherosclerosis in diabetic patients (5).
However, antioxidant therapies such as vitamins E and C
have shown limited beneﬁts in clinical trials targeted at
reducing cardiovascular outcomes (6,7). This has led to
intensive efforts to deﬁne alternative antioxidant strate-
gies for clinical applications (8).
Recent studies by our group have suggested that target-
ing antioxidant defenses, which are reduced in organs
susceptible to injury in the diabetic setting (9), may be an
appropriate strategy (10). Our studies have shown an
involvement of the key antioxidant enzyme, glutathione
peroxidase-1 (GPx1), in diabetes-associated proathero-
genic pathways that included proinﬂammatory and proﬁ-
brotic mediators, suggesting that this antioxidant holds
promise as a therapeutic target (10). Our data are also
supported by clinical ﬁndings where a reduction in GPx1
activity has been linked to an increased risk of cardiovas-
cular disease, both within a diabetic setting and associated
with coronary artery disease (11–13).
Modulation of GPx1 activity can be achieved through
administration of selenium, the essential trace element
found within the active site of GPx1, (14) although this
holds less pharmacologic appeal because of selenium
toxicity (15). In addition, lack of speciﬁcity caused by
incorporation of selenium into several key enzymes makes
this approach less attractive (14). Thus, compounds that
mimic GPx1 activity offer an alternate way to increase
GPx1-like activity (16).
Ebselen, a lipid-soluble low molecular weight seleno-
organic compound and a known GPx1-mimetic, (17) has
shown potential in reducing pathogenesis in various ex-
perimental models (18–20). Of signiﬁcance in the Zucker
diabetic fat rat, a model of type 2 diabetes associated with
the metabolic syndrome, ebselen improved endothelial
dysfunction and renal insufﬁciency (21,22). Furthermore,
data from our laboratory have shown that ebselen reduces
diabetes-associated lesions and proinﬂammatory media-
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has investigated the effects of ebselen on atherosclerosis
and nephropathy, two clinically relevant and often linked
comorbidities, in one animal model. Such a study would
strengthen the notion that oxidative stress underpins these
diabetic complications, and would highlight the effective-
ness of a targeted antioxidant approach against both
conditions.
Consequently, in this study our objectives were as follows:
First, our study investigated whether ebselen protects
against diabetic nephropathy and diabetes-associated athero-
sclerosis in the diabetic ApoE/GPx1-deﬁcient mouse. Sec-
ond, we speciﬁcally chose the ApoE-deﬁcient mouse
additionally lacking Gpx1 to establish whether ebselen re-
plenishes the lack of GPx1 activity. This has been performed
to further clarify the mechanism of action of ebselen in an in
vivo context, as well as strengthen the idea that replenishing
GPx1-like activity may be of therapeutic beneﬁt (11). Finally,
our study also addressed potential pathways affected by
ebselen in a rat kidney cell line.
RESEARCH DESIGN AND METHODS
Animal groups and experimental design. Eight-week-old male ApoE
/GPx
/
double knockout (dKO) mice (10) were rendered diabetic by two intraperito-
neal injections of streptozotocin (Sigma, USA) on consecutive days, at 100
mg/kg/day (10). For comments on group selection, please see the supplemen-
tary appendix available online at http://diabetes.diabetesjournals.org/cgi/
content/full/db10-0195/DC1. Diabetic mice were divided into ebselen-gavaged
and cellulose-gavaged groups. Ebselen (Sapphire Bioscience, Australia), dis-
solved in 5% CM-cellulose (Sigma, USA), was gavaged twice daily at 10 mg/kg
starting at 10 weeks of age. Diabetes was allowed to progress for 10 or 20
weeks. Kidneys from nondiabetic and diabetic ApoE
/ mice rendered
diabetic as detailed above, together with their ebselen-gavaged counterparts,
were also assessed to facilitate comparisons with dKO kidneys in the
development of diabetic renal complications.
Blood sampling, plasma biochemistry, and tissue collection. Plasma was
analyzed for diamicron reactive oxygen metabolites (dROMs), a marker of
hydroperoxides, using the FRAS-4 system as well as glucose, cholesterol,
HDL, and triglycerides using commercial kits (see the supplementary online
appendix for expanded METHODS). Glycated hemoglobin was measured in
erythrocyte lysates by HPLC (Bio-Rad, USA). Urinary albumin excretion was
measured using a mouse albumin ELISA kit (Bethyl Laboratories, USA).
Plasma and urinary creatinine was measured by cation exchange chromatog-
raphy (24).
One kidney was snap-frozen and stored at 70°C for gene expression and
protein studies. The other was divided longitudinally, ﬁxed in 10% neutral
buffered formalin (NBF), and processed for immunohistochemical analysis,
after which 3-m parafﬁn-embedded cross-sections were cut.
Twenty weeks after initiation of diabetes, aortas from diabetic mice or
sham-injected controls were ﬁxed in 10%-NBF for en face assessment of
atherosclerotic lesions. Aortas were stained with Sudan IV and dissected into
arch, thoracic, and abdominal regions, after which photographic images were
quantitated. Aortas from mice that were diabetic for 10 weeks, together with
aged-matched controls, were either snap-frozen in liquid nitrogen and stored
for gene expression studies, or ﬁxed in 10%-NBF and processed for
immunohistochemistry.
Immunohistochemistry. Aortic parafﬁn sections were stained for nitroty-
rosine, 4-hydroxynonenal (4-HNE), vascular endothelial growth factor
(VEGF), connective tissue growth factor (CTGF), NADPH oxidase-2 (Nox2),
and vascular cell adhesion molecule (VCAM-1). Kidney sections were stained
for nitrotyrosine, Nox2, collagen I, and ﬁbronectin. Detailed methods and
antibodies (supplementary Table 1) are described in the online appendix,
including Mouse on Mouse immunodetection to localize antibodies raised in
mouse (4-HNE, VCAM-1). For aortic analysis, three sections of each region
were assessed per mouse, and 7 to 9 mice analyzed per group. Results were
calculated as the percentages of positively-stained tissue and expressed
relative to nondiabetic dKO mice. For glomerular assessments, 20 glomeruli
were analyzed per mouse, and 6 to 8 mice assessed per group. For tubular
staining, 4 to 6 ﬁelds were assessed per kidney and 6 to 8 mice were assessed
per group.
Evaluation of kidney nitrotyrosine using ELISA and urinary 8-isopros-
tane. Nitrotyrosine was assessed in kidney mitochondrial fractions using an
ELISA nitrotyrosine immunoassay kit (Oxis Research). Total protein was
determined using a Pierce BCA kit. Urinary 8-isoprostanes were measured
using a competitive assay per the manufacturer’s recommendations (Cayman
Chemical Company, Ann Arbor, MI).
Quantitative reverse-transcription polymerase chain reaction. RNA
extraction and reverse transcription of aortic samples have been described
previously (10). Total RNA was extracted from kidney cortex. Kidney gene
expression of Nox1, Nox2, Nox4, ﬁbronectin, VEGF, TGF-, CTGF, TNF-,
VCAM-1, MCP-1, -SMA, collagen I, collagen III, collagen IV, GPx1, GPx3,
GPx4, and catalase were analyzed by quantitative RT-PCR as described
previously (10) and in the supplementary online material. Probes and primers
are shown in supplementary Table 2.
Glomerular injury. Three micron-thick kidney sections were stained with
periodic-acid Schiff (PAS) to assess glomerular injury, which was determined
in digital images using Image-Pro Plus 6.0 software (Media Cybernetics) and
determined as the percentage of increased deposition of extracellular matrix
within the glomerulus. The degree of injury was assessed in glomeruli showing
a clearly identiﬁable vascular pole. 20 glomeruli were analyzed per mouse,
and 6 to 8 mice were assessed per group.
Cell culture and immunoblot analysis of normal rat kidney cells. Normal
rat kidney interstitial ﬁbroblasts were maintained in DMEM, and proteins
extracted as described previously. Forty-ﬁve micrograms of protein was
separated on 10% SDS polyacrylamide gels, transferred onto nitrocellulose
membranes, and subjected to primary antibodies against phospho-IKK
ser180/
IKK
ser181, phospho-JNK(Thr183/Tyr185), and phospho-p38. Membranes were
also probed with -tubulin. Antibody binding was detected using the ECL
Advance Western Blotting detection kit and quantiﬁed by densitometry. To
determine whether the observed changes in phosphorylation were caused by
changes in total protein, separate membranes were hybridized with total IKK,
JNK, and p38, and standardized for loading with -tubulin. Phosphorylated
protein was then expressed per total protein.
Statistical analysis. Data were analyzed with one-way ANOVA using Graph-
Pad Prism 5 software. Student-Newman-Keuls multiple comparison was used
to compare group means. P  0.05 was considered signiﬁcant. Results are
expressed as mean  SEM unless otherwise stated.
RESULTS
Phenotypic assessment of ebselen-gavaged ApoE
/
GPx1
/ mice and metabolic parameters after 20
weeks of diabetes. Supplementary Table 3 shows body
weight and metabolic parameters in cellulose- and eb-
selen-gavaged nondiabetic and diabetic dKO mice. Dia-
betic dKO mice have signiﬁcantly lower body weights
compared with nondiabetic controls (P  0.001). Ebselen-
gavage caused a small yet signiﬁcant reduction in body
weight in nondiabetic dKO mice, although this was not
observed in nondiabetic ApoE
/ mice gavaged with eb-
selen (supplementary Table 4). Diabetes was associated
with a signiﬁcant increase in glycated hemoglobin, plasma
glucose, water intake, and urinary output in diabetic dKO
mice compared with nondiabetic counterparts. Diabetes
had no effect on lipids (cholesterol, triglycerides, HDL, and
LDL), and these parameters as well as glucose and gly-
cated hemoglobin were not affected by ebselen-treatment,
emphasizing that ebselen has no effect on glucose or lipid
pathways in diabetic dKO mice. The same parameters are
shown for ApoE
/ mice in supplementary Table 4. Eb-
selen had no effect on any parameters measured in non-
diabetic ApoE
/ mice. Diabetic ApoE
/ mice showed
signiﬁcantly increased glycated hemoglobin, plasma glu-
cose, triglycerides, water intake, and urinary output. No
signiﬁcant differences were noted between untreated and
ebselen-treated diabetic ApoE
/ mice, with the exception
that ebselen-treated diabetic ApoE
/ mice lost less
weight than their untreated diabetic counterparts.
Effect of ebselen on organic hydroperoxides in
plasma and 8-isoprostane in urine. The dROMs test
measures organic hydroperoxides present in plasma and is
proportional to the free radicals from which they form
(25). Our study (supplementary Table 3) shows a signiﬁ-
cant twofold increase in dROMs as a result of diabetes
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signiﬁcantly attenuated by 30% after ebselen treatment
(P  0.001 vs. diabetic dKO). Similarly, 8-isoprostane
levels, a marker of chronic oxidative stress (26), were
increased in diabetic urines and reduced by ebselen (P 
0.05, diabetic plus ebselen vs. diabetic mice; supplemen-
tary Tables 3 and 4).
Effect of ebselen on atherosclerotic lesions. After 20
weeks of diabetes, total aortic plaque was signiﬁcantly
increased in dKO aortas compared with nondiabetic
controls (Fig. 1B vs. Fig. 1A and D; P  0.001). Regional
plaque evaluation showed highly signiﬁcant increases in
the arch (P  0.001), thoracic (P  0.01), and abdominal
(P  0.001) regions in untreated diabetic mice com-
pared with nondiabetic controls (Fig. 1E). Ebselen
reduced total aortic plaque by 57% in diabetic mice
compared with untreated diabetic aortas (Fig. 1, C vs. B
and D; P  0.001), with signiﬁcant regional reductions in
the plaque area of 45% in the arch (P  0.001), 83%
in the thoracic (P  0.05), and 70% in the abdominal
aorta (P  0.01; Fig. 1E). The diabetes-associated
increase in atherosclerosis within the aortic sinus was
not reduced after 10 or 20 weeks of ebselen treatment
(supplementary online Fig. 1).
Effect of ebselen on Nox2, oxidative stress markers
and GPx isoforms 3 and 4 in dKO aortic tissue
Nox2. After 10 weeks of diabetes, aortic Nox2 mRNA
levels increased 14-fold compared with nondiabetic con-
trols (P  0.001; Fig. 2A). There was a marked increase in
Nox2 immunostaining both in the intimal and medial
layers in diabetic aortas of 1.7-fold compared with
nondiabetic counterparts (P  0.05; supplementary online
Figs. 2A and 3A). Ebselen reduced Nox2 mRNA and
protein levels by 60% (P  0.01) and 42% (P  0.05),
respectively, in diabetic aortas compared with untreated
diabetic aortas.
Oxidative stress markers: nitrotyrosine and 4-HNE.
Nitrotyrosine staining of dKO aorta was increased ap-
proximately threefold compared with nondiabetic con-
trols (Fig. 3B and supplementary online Fig. 2B),
although this fell just outside of signiﬁcance. Ebselen
reduced nitrotyrosine levels by 73% in diabetic dKO
aortas compared with untreated diabetic aortas. Simi-
larly, 4-HNE, a major aldehyde product of lipid peroxi-
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FIG. 1. Ebselen reduces diabetes-associated atherosclerosis in the ApoE
/GPx1
/ (dKO) aorta. Sudan IV-stained aortas from (A) nondiabetic,
(B) diabetic, and (C) ebselen-gavaged diabetic dKO mice, 20 weeks after sham or streptozotocin-induced diabetes. Total and regional plaque is
shown in D and E, respectively; Bars, mean  SEM (n  6–10 aortas/group). ***P < 0.001, **P < 0.01 vs. nondiabetic controls; ###P < 0.001,
##P < 0.01, #P < 0.05 vs. diabetic dKO aortas. Abd, abdominal; D, diabetic; Eb, ebselen; ND, nondiabetic; Thor, thoracic. (A high-quality digital
representation of this ﬁgure is available in the online issue.)
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reduced by ebselen (P  0.05; Fig. 3C and supplemen-
tary online Fig. 2C).
Gpx3 and GPx4. Expression of the extracellular GPx3
and the phospholipid hydroperoxide GPx4 is signiﬁcantly
increased in diabetic dKO aorta (P  0.001 and P  0.01,
respectively), while ebselen prevented the diabetes-driven
upregulation of GPx3 and GPx4 (supplementary online
Fig. 3).
Effect of ebselen on pro-atherogenic markers
VEGF and CTGF. After 10 weeks of diabetes, dKO aortas
showed an 17-fold and 7-fold increase in VEGF mRNA
(P  0.001; Fig. 2B) and protein levels, respectively (P 
0.05; Fig. 3D, and supplementary online Fig. 2D), com-
pared with nondiabetic controls. Ebselen signiﬁcantly
attenuated the diabetes-induced increase in VEGF at both
the mRNA (P  0.001) and protein level (P  0.05) back to
that seen in nondiabetic dKO mice. The increase in VEGF
protein was observed in both intimal and medial layers of
the diabetic aorta, and this was attenuated in both of these
layers by ebselen. Analysis of CTGF showed similar trends
with an approximately threefold (Fig. 2C) and approxi-
mately fourfold (Fig. 3E) increase in CTGF mRNA (P 
0.05) and protein (supplementary online Fig. 2E), respec-
tively, which were reduced to nondiabetic levels by
ebselen.
MCP-1 and VCAM-1. After 10 weeks of diabetes, dKO
aortas showed 27-fold (P  0.01; Fig. 2D) and 9-fold
(P  0.001; Fig. 2E) increases in MCP-1 and VCAM-1
mRNA levels, respectively, compared with nondiabetic
dKO controls. Ebselen signiﬁcantly reduced the increases
in both MCP-1 and VCAM-1 mRNA back to basal levels
(P  0.01) in diabetic dKO mice. Ten weeks of diabetes
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FIG. 2. Ebselen attenuates ApoE
/GPx1
/ (dKO) aortic mRNA ex-
pression after 10 weeks of STZ-induced diabetes. (A) Nox2,( B) VEGF,
(C) CTGF,( D) MCP-1, and (E) VCAM-1 quantitative RT-PCR levels
were expressed relative to nondiabetic dKO levels, which were arbi-
trarily assigned a value of 1. Bars, mean  SEM (n  7–9 aortas/group).
***P < 0.001, **P < 0.01, *P < 0.05 vs. nondiabetic dKO aortas; ###P <
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FIG. 3. Ebselen attenuates ApoE
/GPx1
/ (dKO) aortic protein
levels after 10 weeks of STZ-induced diabetes. Representative immun-
histochemical staining for each protein is shown in supplementary
online Fig. 2A–F. Quantitation of immunohistochemical staining within
aortic sections is shown for (A) Nox2, (B) nitrotyrosine (NT), (C)
4-HNE, (D) VEGF, (E) CTGF, and (F) VCAM-1. Values are expressed
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nondiabetic dKO group; #P < 0.05 vs. diabetic dKO group. a.u.,
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nondiabetic.
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nohistochemical analysis (supplementary online Fig. 2F)
of aortas from dKO mice (Fig. 3F; P  0.05 vs. nondiabetic
dKO aortas), which ebselen signiﬁcantly reduced by 68%
(Fig. 3F; P  0.05 vs. diabetic dKO aortas).
Assessment of diabetic renal injury in dKO mice
Albuminuria and creatinine clearance. Diabetes
caused a signiﬁcant increase in urinary albumin excre-
tion rate (AER) in both the ApoE
/ (Fig. 4A, 3-fold;
P  0.01) and dKO (4.8-fold; P  0.001) mice com-
pared with nondiabetic counterparts after 10 weeks of
diabetes. Furthermore, AER was signiﬁcantly greater in
diabetic dKO mice than in diabetic ApoE
/ mice (2.8-
fold; P  0.01). Ten weeks of ebselen gavage had no
effect on AER in diabetic ApoE
/ mice, but signiﬁ-
cantly reduced albuminuria in diabetic dKO mice (P 
0.01). Similar results were obtained after 20 weeks of
diabetes (supplementary online Fig. 4), where ebselen
normalized the diabetes-driven increase in AER in dia-
betic dKO mice (P  0.05 vs. diabetic dKO mice).
Twenty weeks of ebselen-gavage signiﬁcantly reduced
the diabetes-induced increase in creatinine ﬁltration in
both ApoE
/ (P  0.001) and dKO mice (P  0.05)
(supplementary Tables 3 and 4).
Glomerular injury. The percentage of PAS-positive ma-
terial, indicative of mesangial expansion, was signiﬁcantly
increased after 10 and 20 weeks of diabetes in dKO
glomeruli (Fig. 4Bii vs. Bi and C; P  0.001 for both time
points). The expansion was progressive, with an 30%
increase at 20 weeks compared with 10 weeks of diabetes
(Fig. 4C; P  0.001). Diabetic dKO glomeruli also displayed
signiﬁcantly more PAS staining compared with diabetic
ApoE
/ glomeruli after 10 weeks of diabetes (Fig. 4D;
P  0.001). Ebselen reduced the percentage of PAS
staining in diabetic dKO glomeruli after 10 and 20 weeks of
diabetes (Fig. 4C; P  0.001).
Effect of ebselen on nitrotyrosine, Nox, and GPx
isoforms 3 and 4 in diabetic kidney
Nitrotyrosine. After 20 weeks of diabetes, dKO kidneys
showed signiﬁcantly increased levels of nitrotyrosine in
both tubules and glomeruli compared with nondiabetic
dKO kidneys (Fig. 5B vs. A, and I [tubules; P  0.001]; Fig.
5F vs. Fig. 5E and J [glomeruli; P  0.001]), as well as
diabetic ApoE
/ kidneys (Fig. 5I and J; P  0.001).
Ebselen reduced dKO nitrotyrosine levels back to nondi-
abetic levels in both tubules (Fig. 5C vs. B; and Fig. 5I; P 
0.01) and glomeruli (Fig. 5G vs. F; and Fig. 5J; P  0.001).
These results were conﬁrmed by ELISA when ebselen
signiﬁcantly reduced nitrotyrosine levels after 20 weeks of
diabetes in the mitochondrial fraction of dKO kidneys
(diabetic dKO: 5.04  0.55 vs. diabetic dKOEbselen:
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signiﬁcantly reduced after 10 weeks of treatment in the diabetic dKO kidney, ##P < 0.01 vs. diabetic dKO, ***P < 0.001 and **P < 0.01 vs.
nondiabetic counterparts, n  4–8 urines/group, Bars, geometric mean  error bars. B: Representative photomicrographs of PAS-stained
glomeruli, (i) nondiabetic dKO, (ii) diabetic dKO, (iii) diabetic dKOEb. C: Ebselen signiﬁcantly attenuated PAS staining after 10 and 20 weeks
of treatment in diabetic dKO kidneys, ###P < 0.001 vs. diabetic dKO kidneys; ***P < 0.001 vs. nondiabetic age-matched dKO kidneys. D: PAS
staining of kidneys showed signiﬁcantly more damage in the diabetic dKO kidney versus diabetic ApoE
/ controls (***P < 0.001 vs. diabetic
ApoE
/ kidneys), ***P < 0.001 vs. nondiabetic kidneys; n  6–9 mice/group and at least 20 glomeruli/mouse. 10w, 10 weeks of diabetes; 20w, 20
weeks of diabetes; D, diabetic; Eb, ebselen; ND, nondiabetic. (A high-quality digital representation of this ﬁgure is available in the online issue.)
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Nox. We examined the gene expression of three isoforms
of Nox (Nox 1, 2, 4) in the cortex of ApoE
/ and dKO
mice (Fig. 6A and supplementary online Fig. 5). Expres-
sion was signiﬁcantly increased in dKO kidneys (P  0.001
for Nox2 and Nox4; and P  0.05 for Nox1) compared with
nondiabetic controls. Furthermore, diabetic dKO mRNA
expression of Nox2 and Nox4 was signiﬁcantly increased
above that of diabetic ApoE
/ kidneys (P  0.001). Nox2
protein was signiﬁcantly increased in both the glomeruli
and tubules (Fig. 6B) of diabetic dKO kidneys compared
with nondiabetic controls (P  0.05 for glomeruli; Fig. 6C
and P  0.01 for tubules; Fig. 6D), and was signiﬁcantly
increased compared with diabetic ApoE
/ kidneys (P 
0.05 for glomeruli and P  0.01 for tubules). Ebselen
signiﬁcantly reduced the diabetes-driven increases in
Nox2 (P  0.001) and Nox4 (P  0.001) expression in the
diabetic dKO kidney, as well as Nox1 expression in the
diabetic ApoE
/ kidney (P  0.001). Furthermore, eb-
selen decreased Nox2 protein in the glomeruli and tubules
(P  0.01) of diabetic dKO kidneys.
Gpx3 and GPx4. GPx3 and GPx4 expression is signiﬁ-
cantly increased in diabetic dKO kidneys (P  0.01 and
P  0.001, respectively) compared with diabetic ApoE
/
kidneys, while ebselen prevented this increase (see sup-
plementary online Fig. 6).
Effect of ebselen on proﬁbrotic and proinﬂammatory
mediators and extracellular matrix proteins in dia-
betic kidneys. The mRNA expression of a range of
proﬁbrotic growth factors (TGF-, CTGF), proinﬂamma-
tory mediators (MCP-1, VCAM-1, and TNF-), -smooth
muscle actin (-SMA) and proﬁbrotic markers (collagen I,
III, IV, and ﬁbronectin) were assessed in ApoE
/ and dKO
nondiabetic and diabetic kidneys (supplementary online
Figs. 7 and 8). TGF-, collagen I, collagen III, MCP-1,
VCAM-1 (P  0.001) and ﬁbronectin mRNA levels (Fig. 7A;
P  0.001) were signiﬁcantly increased in diabetic dKO
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FIG. 5. The H2O2-mediated increase in nitrotyrosine (NT) is reduced by ebselen in the diabetic ApoE
/GPx
/ (dKO) kidney. A–D:
Representative photomicrographs of kidney tubules after 20 weeks of diabetes. (A) nondiabetic dKO, (B) diabetic dKO, (C) diabetic dKO  Eb,
and (D) negative control which consisted of species-matched nonimmune IgG in place of primary antibody. E–H: Representative photomicro-
graphs of kidney glomeruli after 20 weeks of diabetes. Nondiabetic dKO (E); Diabetic dKO (F); diabetic dKO  Eb (G); and negative control which
consisted of species-matched nonimmune IgG in place of primary antibody (H). Quantitation of nitrotyrosine-stained tubules and glomeruli is
shown in I and J, respectively. ***P < 0.001; diabetic dKO versus diabetic ApoE
/ kidneys. ##P < 0.01 and ###P < 0.001 vs. diabetic dKO kidneys.
Bars, mean  SEM; n  6–8 kidneys/group. a.u., arbitrary units; D, diabetic; Eb, ebselen; ND, nondiabetic. (A high-quality digital representation
of this ﬁgure is available in the online issue.)
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/ kidneys. Eb-
selen signiﬁcantly reduced the expression of all genes
investigated in the diabetic dKO and ApoE
/ kidneys,
with the exception of collagen III and MCP-1 in the
diabetic ApoE
/ kidney where expression was not differ-
ent from nondiabetic levels.
Two proﬁbrotic genes were chosen to verify these
changes at the protein level. Fibronectin, both within the
glomeruli and tubules, was signiﬁcantly increased in dia-
betic dKO kidneys (Fig. 7C and D) compared with diabetic
ApoE
/ kidneys (P  0.05 and P  0.01 for glomeruli and
tubules, respectively). Ebselen signiﬁcantly attenuated the
diabetes-related increase in ﬁbronectin in the glomeruli
(Fig. 7C; P  0.05) and tubules (Fig. 7D; P  0.01) to levels
similar to that observed in nondiabetic kidneys. Collagen I
was detected mainly in brush borders of proximal tubules
(supplementary online Fig. 9), but also in surrounding
glomeruli and tubules as previously reported (28). Colla-
gen I was upregulated in the tubular compartment in
diabetic dKO kidneys, particularly within the brush bor-
ders of the tubules. In agreement with our RT-PCR data
(supplementary online Fig. 8B), collagen I protein was also
signiﬁcantly increased in diabetic dKO kidneys compared
with diabetic ApoE
/ kidneys (P  0.001, supplementary
online Fig. 9). Ebselen caused signiﬁcant reductions in
collagen I levels in diabetic dKO kidneys (supplementary
online Fig. 9; P  0.001).
Effect of ebselen on antioxidants in the diabetic dKO
kidney. We investigated the expression of other antioxi-
dants in addition to GPx1 that are part of the antioxidant
pathway (29). Protein analysis by Western blots (supple-
mentary online Fig. 10) conﬁrmed the lack of GPx1 in the
dKO kidney, in agreement with our previous studies in this
model (30,31). Ebselen caused a small yet signiﬁcant
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FIG. 6. The H2O2-mediated increase in Nox2 is reduced by ebselen in
the diabetic ApoE
/GPx1
/ (dKO) kidney. A: Quantitative RT-PCR
analysis of Nox2 in ApoE
/ and dKO kidneys after 20 weeks of
diabetes; n  8–10 kidneys/group. B: Representative photomicrographs
of kidney glomeruli (i–iv) and tubules (v–viii); nondiabetic dKO (i and
v); diabetic dKO (ii and vi); diabetic dKOEb (iii and vii); and negative
control which consisted of species-matched nonimmune IgG in place of
primary antibody (iv and viii). C and D: Quantitation of Nox2 protein
within glomeruli and tubules, respectively. ***P < 0.001; **P < 0.01;
*P < 0.05 diabetic dKO vs. diabetic ApoE
/ kidneys; and versus
nondiabetic counterparts. ##P < 0.01 and ###P < 0.001 vs. diabetic
dKO kidneys. Bars, mean  SEM; n  20 glomeruli/kidney and 4–6
kidneys/group and n  6 tubular ﬁelds/kidney and at least 5 kidneys/
group. a.u., arbitrary units; D, diabetic; Eb, ebselen; ND, nondiabetic.
(A high-quality digital representation of this ﬁgure is available in the
online issue.)
ND ApoE
ND ApoE + Eb
D ApoE
D ApoE + Eb
ND dKO
ND dKO + Eb
D dKO
D dKO + Eb
0
2
4
6
8 *** ###
*** ###
***
F
i
b
r
o
n
e
c
t
i
n
 
m
R
N
A
(
a
.
u
.
)
ND ApoE
ND ApoE + Eb
D ApoE
D ApoE + Eb
ND dKO
ND dKO + Eb
D dKO
D dKO + Eb
0
10
20
30
40
50 ** ##
* #
F
i
b
r
o
n
e
c
t
i
n
 
p
r
o
t
e
i
n
 
(
a
.
u
)
ND ApoE
ND ApoE + Eb
D ApoE
D ApoE + Eb
ND dKO
ND dKO + Eb
D dKO
D dKO + Eb
0.0
2.5
5.0
7.5
10.0
12.5
* #
*
F
i
b
r
o
n
e
c
t
i
n
 
p
r
o
t
e
i
n
 
(
a
.
u
)
A
C
D
B
Glomeruli
Tubules
i 
ii 
iii 
vi 
v 
iv 
vii 
viii 
FIG. 7. The H2O2-mediated increase in ﬁbronectin is reduced by
ebselen in the diabetic ApoE
/GPx1
/ (dKO) kidney. A: Quantitative
RT-PCR analysis of ﬁbronectin in ApoE
/ and dKO kidneys after 20
weeks of diabetes; n  7–10 kidneys/group. B: Representative photomi-
crographs of kidney glomeruli (i–iv) and tubules (v–viii); nondiabetic
dKO (i and v); diabetic dKO (ii and vi); diabetic dKOEB (iii and vii);
and negative control which consisted of species-matched nonimmune
IgG in place of primary antibody (iv and viii). C and D: Quantitation of
ﬁbronectin protein within glomeruli and tubules, respectively. ***P <
0.001; **P < 0.01; *P < 0.05 and ###P < 0.001; ##P < 0.01; #P < 0.05
as indicated by horizontal bars. Bars, mean  SEM; n  20 glomeruli/
kidney and 4–6 kidneys/group and n  6 tubular ﬁelds/kidney and at
least 5 kidneys/group. a.u., arbitrary units; D, diabetic; Eb, ebselen; ND,
nondiabetic. (A high-quality digital representation of this ﬁgure is
available in the online issue.)
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/ kidneys
compared with untreated nondiabetic controls (P  0.05).
No signiﬁcant differences in Sod1 or catalase levels were
detected in any of the groups on Western blot analysis.
In vitro analysis of ebselen in normal rat kidney cells.
Initial experiments established optimal treatment time and
dosage with H2O2 (30 min, at 1 mmol/l; data not shown) for
increased expression of P-IKK, P-JNK, and P-p38. Pretreat-
ment with 0.03 mol/l ebselen for 30 min, followed by
treatment with 1 mmol/l H2O2 for 30 min, signiﬁcantly
reduced H2O2-mediated increases in phosphorylation of
p38, IKK, and JNK (Fig. 8; P  0.05).
DISCUSSION
This study shows that the synthetic antioxidant, ebselen,
reduces atherosclerosis and renal injury in diabetic ApoE/
GPx1-deﬁcient mice. Atherosclerosis was attenuated in
the major regions of the aorta. However, one region
unaffected by ebselen was the sinus, in agreement with a
growing list of studies showing the resistant nature of this
region to pharmacologic intervention (23,32). The reduc-
tion in atherosclerosis was accompanied by signiﬁcant
reductions in vascular oxidative stress as reﬂected by
reduced staining for two established oxidative stress
markers, 4-HNE and nitrotyrosine, a reduction in the Nox2
subunit of NADPH oxidase (Nox), an enzyme implicated in
the generation of vascular ROS, and a reduction in plasma
hydroperoxides and urinary 8-isoprostanes. Furthermore,
proinﬂammatory and proatherogenic mediators associated
with the atherosclerotic phenotype (VCAM-1, MCP-1,
CTGF, and VEGF) were reduced by ebselen in the diabetic
ApoE/GPx1-deﬁcient aorta. These data support the notion
of Blankenberg et al. (11) that bolstering GPx-like activity
reduces atherosclerosis, and it is in agreement with our
previous study where lack of GPx1 greatly accelerated
plaque deposition in the aorta of diabetic ApoE
/GPx1
/
mice (10).
This study has also shown that in addition to its antiath-
erosclerotic potential, the GPx1-mimetic ebselen prevents
renal functional changes such as albuminuria and various
renal structural changes and inﬂammatory responses associ-
ated with nephropathy in diabetic mice that also had a
deletion in GPx1. Our study strengthens the ﬁndings of Reddi
and Bollineni (33), where a deﬁciency in selenium led to
increased oxidative stress and accelerated nephropathy in
diabetic rats, and it is in agreement with Chander et al. (22)
where ebselen improved renal outcomes in the Zucker dia-
betic fat rat. Importantly, by improving both renal and
atherogenic outcomes in the diabetic ApoE/GPx1-deﬁcient
model, our study suggests that ebselen is effective as a
monotherapy against both diabetes-associated conditions.
Furthermore, this study has provided in vivo evidence that
ebselen, in its ability to act as an antioxidant, functionally
replenishes the lack of GPx1 in this murine model. Two
pieces of evidence support this notion. First, ebselen lowered
plasma levels of reactive oxygen metabolites, implying that
ebselen acts as an antioxidant in the removal of ROS such as
hydroperoxides. Second, ebselen reduced nitrotyrosine lev-
els, a marker of peroxynitrite-mediated protein damage and a
function mostly attributed to GPx1 in its capacity to act as
peroxynitrite reductase (34,35). In addition, our data showing
an ebselen-mediated reduction in nitrotyrosine within the
mitochondrial fraction of the diabetic kidney adds further
information about the mechanism of ebselen action. It is well
accepted that mitochondrial ROS play a signiﬁcant role in
diabetes-associated injury (36), particularly that seen in dia-
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FIG. 8. Ebselen abrogates H2O2-mediated increases in (A and D) P-p38; (B and E) P-IKK, and (C and F) P-JNK protein in normal rat kidney cells.
A representative gel with its internal -tubulin control (Aii, Biv, and Cvi) is shown above the quantitation for each protein. Lane 1  untreated
cells; lane 2  serum-starved (SS) cells for 4 h; lane 3  DMSO-treated cells; lane 4  DMSO  1 mmol/l H2O2-treated cells; lane 5  1 mmol/l
H2O2 treated cells; lane 6  0.03 mol/l ebselen-treated cells; and lane 7  1 mmol/l H2O20.03 mol/l ebselen-treated cells. Arrows point to the
two isoforms of P-JNK. Phosphorylated protein was quantitated relative to total protein (total protein levels are shown in supplementary online
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trite within this compartment may have contributed to the
protective effects observed in this study. Our data also
suggest that the protective effects of ebselen in diabetic dKO
mice occur independently of any compensatory effects on
the major antioxidants, Sod1, catalase, or the isoforms of
GPx (for more detailed discussion please see supplementary
online appendix, points 1 and 2).
Our study has also shown some differential effects of
ebselen in the presence of GPx1, since ebselen had no
effect in reducing diabetes-associated proteinuria nor var-
ious markers of oxidative stress such as nitrotyrosine or
Nox2 in diabetic ApoE
/ kidneys. It remains to be
ascertained if the degree of GPx1-depletion often seen in
the diabetic milieu is an important predisposing factor for
responsiveness to ebselen (also see the supplementary
online appendix, point 3). Furthermore, ebselen was asso-
ciated with variable effects on body weight, albeit these
changes were modest. In addition, this treatment was
associated with a reduction in creatinine clearance in both
diabetic ApoE
/ and dKO mice, a phenomenon not
observed in nondiabetic animals. It is likely that this
represents a protective effect of ebselen on renal hyperﬁ-
tration rather than a deleterious effect on renal function,
since after ebselen treatment, creatinine clearance was
still within the normal range. The underlying explanation
for these renal hemodynamic effects of ebselen remain to
be elucidated.
This study has also demonstrated that lack of GPx1 on
an ApoE-deﬁcient background accelerates pathologic
changes associated with diabetic nephropathy. Interest-
ingly, our previous study failed to show a role for GPx1 in
reducing diabetic nephropathy in C57Bl/J6 diabetic mice
(30). This was an unexpected ﬁnding since the high
glucose environment within the diabetic kidney is known
to be a strong inducer of ROS (37), and furthermore, GPx1
is the major antioxidant in the removal of hydrogen and
lipid peroxides within the kidney (31). However, the
signiﬁcance of a lack of GPx1 may not have been properly
revealed since lipids, known to be important in the devel-
opment of diabetic nephropathy (38), are unaltered in the
diabetic C57Bl/J6 model. Indeed, hyperlipidemia is now
recognized as a major phenotypic feature in people who
are prone to nephropathy (39). In the present study we
reassessed the role of GPx1 in the development of diabetic
nephropathy against a background of elevated lipids in
diabetic ApoE/GPx1-dKO mice. We now show increased
albuminuria which is associated with pathologic changes
that include mesangial expansion and upregulation of
proﬁbrotic (collagen I and III, ﬁbronectin, and TGF-)
and proinﬂammatory mediators (VCAM-1, MCP-1) in dia-
betic ApoE/GPx1-dKO kidneys compared with diabetic
ApoE
/ controls. Thus, we have conﬁrmed a role for
GPx1 in limiting and/or preventing diabetic nephropathy in
the clinically relevant milieu of increased lipids known to
accompany diabetes (38,39). It is also noteworthy that lack
of GPx1 caused a further upregulation of the predomi-
nantly tubular collagens, collagen I and III, but not the
major basement membrane type IV collagen, in the dia-
betic kidney. Types I and III collagens are expressed
mainly in the interstitial regions, whereas type IV collagen
plays a signiﬁcant role in glomerular pathology (40,41). It
is therefore possible that GPx1 plays a role in the protec-
tion of the interstitium against extracellular matrix depo-
sition and inﬂuences tubulointerstitial injury.
A major deﬁciency in animal models of diabetic ne-
phropathy has been the absence of a demonstrated con-
current increase in cardiovascular disease (42). This is
particularly important in the design of effective treatments
against both diabetes-associated atherosclerosis and dia-
betic nephropathy, since it is becoming increasingly ap-
preciated that accelerated cardiovascular disease is a
common phenomenon in subjects with diabetic nephrop-
athy (43). Together with our previous study in which we
showed accelerated diabetes-associated atherosclerosis in
aortas of diabetic ApoE
/GPx1
/ mice (10) and the
current study showing increased renal injury in these
mice, we believe that diabetic ApoE
/GPx1
/ mice are
a useful tool in which to test GPx1-mimetic antioxidant
therapies that may be effective against both complications.
Finally, our in vitro studies in rat normal rat kidney cells
suggest that ebselen mediates its renoprotective effects via
pathways that include the modulation of p38, JNK, and IKK.
By preventing or limiting phosphorylation of the proinﬂam-
matory mediator I
B-kinase (IKK), which in turn regulates
the transcription factor NF-
B, ebselen plays a pivotal role in
limiting the activation of proinﬂammatory genes. Likewise,
by reducing the H2O2-mediated phosphorylation of the
stress-activated kinase JNK, ebselen modulates a kinase that
is involved in the activation of the transcription factor AP-1.
The strong inhibition by ebselen of the phosphorylation of
the MAP-kinase family member p38 suggests that ebselen
affects H2O2-mediated signal transduction and is in agree-
ment with previous studies in HUVECs (44). Together with
our previous data in human aortic endothelial cells (HAECs),
these new data strengthen the notion that ebselen impacts
positively on proinﬂammatory pathways, not only in endo-
thelial cells, but also within kidney cells to limit proinﬂam-
matory processes.
In conclusion, this study shows that ebselen limits the
development of two major diabetic vascular complica-
tions, namely diabetes-associated atherosclerosis and dia-
betic nephropathy in ApoE/GPx1-deﬁcient mice. This
approach of GPx1 repletion via mimetics of GPx1 offers an
alternative therapeutic antioxidant strategy that is worthy
of further investigation.
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